Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Carlson J, McCluggage W
. Reclassifying endometrial carcinomas with a combined morphological and molecular approach. Curr Opin Oncol. 2019; 31(5):411-419.
DOI: 10.1097/CCO.0000000000000560.
View
2.
Jamieson A, Bosse T, McAlpine J
. The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer. Ther Adv Med Oncol. 2021; 13:17588359211035959.
PMC: 8366203.
DOI: 10.1177/17588359211035959.
View
3.
Vermij L, Smit V, Nout R, Bosse T
. Incorporation of molecular characteristics into endometrial cancer management. Histopathology. 2019; 76(1):52-63.
PMC: 6972558.
DOI: 10.1111/his.14015.
View
4.
Leon-Castillo A, de Boer S, Powell M, Mileshkin L, MacKay H, Leary A
. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. J Clin Oncol. 2020; 38(29):3388-3397.
PMC: 7527156.
DOI: 10.1200/JCO.20.00549.
View
5.
Casey L, Singh N
. POLE, MMR, and MSI Testing in Endometrial Cancer: Proceedings of the ISGyP Companion Society Session at the USCAP 2020 Annual Meeting. Int J Gynecol Pathol. 2020; 40(1):5-16.
DOI: 10.1097/PGP.0000000000000710.
View